{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.90","upperLimit":"28.7","value":"8.3"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"16.2","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"7.20","value":"0"},{"groupId":"OG003","lowerLimit":"0.60","upperLimit":"19.0","value":"5.3"},{"groupId":"OG004","lowerLimit":"0","upperLimit":"12.7","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"17"}],"units":"Participants"}],"description":"Overall response rate was defined as percentage of participants documented to have unconfirmed CR or PR according to RECIST v1.1 as the best response. CR was defined as disappearance of all lesions, PR was defined as at least a 30% decrease in the sum of the LD of lesions, taking as reference the baseline sum LD.","groups":[{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, once daily (QD) for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 20 cycles. Participants with locally advanced or metastatic solid tumors with no standard therapeutic alternative in the United States were included in this cohort.","id":"OG000","title":"Western Safety Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 4 cycles. Participants with metastatic pancreatic cancer who had progressed after at least 1 line of standard chemotherapy were included in this cohort.","id":"OG001","title":"Pancreatic Cancer Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 12 cycles. Participants with metastatic CRC who had progressed after at least 2 lines of previous standard chemotherapy were included in this cohort.","id":"OG002","title":"Metastatic CRC Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 8 cycles. Participants with metastatic sqEC who had progressed after at least 1 line of standard chemotherapy were included in this cohort.","id":"OG003","title":"sqEC Cohort"},{"description":"TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 18 cycles. Participants with metastatic sqNSCLC who had progressed after at least 2 lines of standard treatment were included in this cohort.","id":"OG004","title":"sqNSCLC Cohort"}],"paramType":"NUMBER","populationDescription":"Response-evaluable Analysis Set included all participants who received at least 1 dose of study drug, had measurable disease at Baseline, and had at least 1 post-baseline response assessment.","reportingStatus":"POSTED","timeFrame":"From first dose up to end of treatment (Up to approximately 14 months)","title":"Overall Response Rate (CR and PR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}